Liver carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The frequency of GSTP1 promoter hypermethylation is significantly higher in HCC than in nontumorous tissues (p = 0.022) from HBsAg-positive patients, but not the HBsAg-negative controls (p = 0.289).
|
17534893 |
2007 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A real-time PCR assay with glutathione S-transferase pi (GSTP1) gene was used to measure cell-free DNA levels in the sera of 52 patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV), which included 30 HCV carriers without known HCC and 16 HCV-negative non-cancer patients (controls).
|
17214331 |
2007 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the studied polymorphisms affecting GSTP1, GSTA1 and GSTM3 genes are probably not related to the risk of developing hepatocellular carcinoma in the studied population.
|
17716224 |
2007 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The hypermethylated status of the promoter regions of p16INK4a, RASSF1A, E cadherin, and GSTP1 was observed in 10 (40%), 14 (56%), 6 (24%), and 12 (48%) of 25 patients with hepatocellular carcinoma, respectively.
|
16613325 |
2006 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data indicate that the epigenetic aberrance of promoter CpG island hypermethylation of the GSTP1 gene may contribute to the hepatopathogenesis of HCC and is a potential valuable biomarker for noninvasive disease monitoring and HCC early diagnosis.
|
16527261 |
2006 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GSTP1 expression by immunohistochemical staining of HCC tissue samples was significantly associated with methylation status.
|
15808399 |
2005 |
Liver carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
GSTP1 inactivation via CpG island hypermethylation in hepatocellular carcinoma (HCC) was previously reported, but the involvement of NQO1 in HCC is not well known.
|
15763338 |
2005 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The genes frequently methylated in HCC were APC (81.7%), GSTP1 (76.7%), RASSF1A (66.7%), p16 (48.3%), COX-2 (35%), and E-cadherin (33.3%).
|
14507645 |
2003 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Immunohistochemical expression of pi class glutathione S-transferase and alpha-fetoprotein in hepatocellular carcinoma and chronic liver disease.
|
14714299 |
2003 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most frequently methylated TSGs in HCC were: SOCS-1 (65%), GSTP (54%), APC (53%), E-cadherin (49%), and p15 (49%).
|
12937151 |
2003 |
Liver carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
No association between GSTP1 gene aberrant promoter methylation and prognosis in surgically resected hepatocellular carcinoma patients from the Basque Country (Northern Spain).
|
12895264 |
2003 |
Liver carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
These data indicate that epigenetic silencing of GSTP1 gene expression by CpG island DNA hypermethylation is common in human HBV-associated HCC.
|
11948118 |
2002 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
During the pathogenesis of human hepatocellular carcinoma (HCC), the CpG island encompassing the pi-class glutathione S-transferase gene (GSTP1) becomes hypermethylated.
|
11960994 |
2002 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
We report here that inhibition of transcription from hypermethylated GSTP1 promoters in Hep3B HCC cells, which fail to express GSTP1 mRNA or GSTP1 polypeptides, appears to be mediated by MBD2.
|
11960994 |
2002 |
Liver carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Using a PCR assay, somatic GSTP1 <CpG island> DNA hypermethylation was also detected in HCC DNA from 17 of 20 HCC cases.
|
10717233 |
2000 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Highly metastatic hepatocellular carcinomas induced in male F344 rats treated with N-nitrosomorpholine in combination with other hepatocarcinogens show a high incidence of p53 gene mutations along with altered mRNA expression of tumor-related genes.
|
9029167 |
1997 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, levels of transcript were significantly elevated (up to 16-fold) in total RNA derived from bladder and ureteric carcinomas, with the highest levels of elevation approaching those previously found only for the GST-P gene in experimentally induced rodent hepatocellular carcinomas.
|
3359415 |
1988 |